Iambic Taps Lambda’s GPU Power to Advance AI Drug Discovery Model
Lambda, a GPU cloud company built by AI engineers for AI engineers, announced a deepened collaboration with Iambic Therapeutics, a clinical-stage biotech company pioneering AI-powered drug development. As part of this partnership, Lambda will provide Iambic with an NVIDIA HGX B200 cluster to support the continued training and scaling of Enchant, Iambic’s industry-leading transformer model for molecular property prediction.
Powering the Next Generation of Drug Discovery
Enchant is a multi-modal, transformer-based AI model specifically designed to predict a wide range of clinical and preclinical properties of drug molecules. This includes biological, physicochemical, pharmacokinetic, metabolic, and safety-related attributes that are essential for drug viability and clinical success.
With Enchant, Iambic enables scientists to make high-confidence predictions even in scenarios with sparse data—one of the most persistent challenges in early-stage drug discovery. The recently released Enchant v2 extends this capability even further, providing accurate forecasts across dozens of critical endpoints that traditionally require time-consuming and expensive lab testing.
Enhancing Model Scale with Lambda’s NVIDIA HGX B200 Cluster
The new agreement between Iambic and Lambda focuses on scaling Enchant’s capabilities through advanced computing infrastructure. By utilizing Lambda’s NVIDIA HGX B200 cluster, Iambic aims to accelerate training speed, improve prediction accuracy, and increase the number of molecular endpoints the model can assess.
“With the release of Enchant v2, we demonstrated both the model’s accuracy and scalability, and we believe we can rapidly build on these gains through model scale alone,” said Matt Welborn, PhD, Vice President of Machine Learning at Iambic. “We are expanding our successful relationship with Lambda to an NVIDIA HGX B200 cluster, which will accelerate this opportunity and the breadth of preclinical and clinical endpoints Enchant can predict. This increases both the likelihood of a molecule’s success in human trials and the overall efficiency of drug development.”
AI Predictions Surpassing Traditional Lab Methods
One of the most significant implications of Enchant is its potential to outperform traditional lab-based testing in certain contexts. Iambic researchers have shown that Enchant can, in some cases, predict in vivo drug clearance more accurately than in vitro experiments—a critical leap forward as regulatory agencies increasingly encourage the use of in silico methods in drug development.
The ability to make faster, more accurate predictions using AI means that researchers can better prioritize drug candidates, design more efficient clinical trials, and optimize multiple drug properties simultaneously. This multi-parameter optimization can reduce the time and cost associated with bringing a new drug to market, ultimately benefitting patients in need.
Scaling Seamlessly with Lambda’s AI-First Infrastructure
Lambda’s infrastructure, including its 1-Click Clusters, has enabled Iambic to quickly validate new ideas and scale their model development with minimal friction. The move to the NVIDIA HGX B200 cluster represents a significant step forward in performance and scalability.
“We’re thrilled to deepen our partnership with Iambic, a leader in AI-driven drug discovery,” said Robert Brooks IV, Founding Team Member and VP of Revenue at Lambda. “By leveraging Lambda’s 1-Click Clusters for rapid testing and validation, Iambic was able to seamlessly scale to an NVIDIA HGX B200 cluster to accelerate breakthroughs in life sciences.”
Looking Ahead: AI at the Core of Future Drug Development
As the pharmaceutical industry increasingly turns to AI to address the high costs and long timelines of drug discovery, partnerships like the one between Iambic and Lambda highlight the transformative potential of combining state-of-the-art models with next-generation compute infrastructure.
Together, they are pushing the boundaries of what’s possible in predictive modeling, with the goal of delivering more effective medicines to patients faster and more efficiently than ever before.
To learn more about Lambda’s cloud offerings for AI training and inference, click here.
About Iambic’s AI-Driven Discovery Platform
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence.
About Iambic Therapeutics
Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at Iambic.ai
About Lambda
Lambda was founded in 2012 by AI engineers with published research at the top machine learning conferences in the world. Our goal is to become the #1 AI compute platform serving developers across the entire AI development lifecycle. We enable AI engineers to easily, securely and affordably build, test and deploy AI products at scale. Our product portfolio spans from on-prem GPU hardware to hosted GPUs in the cloud. Lambda’s mission is to create a world where access to computation is as effortless and ubiquitous as electricity.
